Case Studies

Challenge: A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...

An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...

Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...

Challenge: Our client was a leading UK research institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita...

Challenge: A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.

Challenge: A university commercialization institute asked Alacrita to review its technology for 3D printed, customised silicone medical products. The main task was to determine the prospective value...